阿加曲班全身输注与冲洗液用于疑似肝素诱导性血小板减少症的经皮心室辅助装置患者
本文报告一例33岁男性使用Impella经皮心室辅助装置并疑似肝素诱导性血小板减少症(HIT)的病例,在停用所有肝素产品后采用阿加曲班全身输注(1000 μg/mL,0.2 μg/kg/min)联合阿加曲班冲洗液(0.05 mg/mL),患者达到治疗性活化部分凝血活酶时间,未发生出血或血栓。
要点
- Impella pVAD患者出现血小板减少时应怀疑HIT,4T评分可用于评估概率。
- 疑似HIT时停用肝素,可考虑阿加曲班全身输注联合冲洗液方案。
- 该方案在本例中达到治疗性aPTT且无出血或血栓事件。
核心结论
- 对使用Impella pVAD且疑似HIT的多器官功能障碍患者,阿加曲班全身输注联合冲洗液可达治疗性aPTT且未发生出血或血栓。
研究设计与样本
- 单例病例报告:33岁男性,接受VA-ECMO、Impella pVAD和连续静脉-静脉血液滤过,后行主动脉瓣置换术。
主要发现
- 患者血小板计数最低降至17 × 103/μL(住院第13天),4T评分计算为4。
- 住院第15天停用所有肝素产品,开始阿加曲班全身输注1000 μg/mL、速率0.2 μg/kg/min,冲洗液为阿加曲班0.05 mg/mL。
- 全身输注速率维持0.2 μg/kg/min,阿加曲班总剂量平均低于0.25 μg/kg/min。
- 患者达到治疗性活化部分凝血活酶时间,无需调整全身阿加曲班输注,未发生出血或血栓。
- 住院第21天患者转至另一机构。
关键数值与推荐
- 阿加曲班全身输注浓度1000 μg/mL,速率0.2 μg/kg/min;冲洗液浓度0.05 mg/mL。
- 阿加曲班总剂量平均低于0.25 μg/kg/min。
- 4T评分计算为4。
临床怎么用
- 对Impella pVAD患者出现血小板减少并疑似HIT时,可考虑停用肝素并采用阿加曲班全身输注联合冲洗液方案。
- 使用期间应监测活化部分凝血活酶时间以评估抗凝效果,并观察出血或血栓事件。
局限性
- 单例病例报告,结果不能推广至所有pVAD患者。
- 原文指出需要进一步研究评估阿加曲班冲洗液在pVAD患者中的安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Thrombocytopenia can occur when using an Impella percutaneous ventricular assist device (pVAD), and heparin-induced thrombocytopenia (HIT) is often suspected. Data on heparin- and anticoagulant-free purge solutions in these devices are limited. Previous case reports have described argatroban-based purge solutions, both with and without systemic argatroban, at varying concentrations in patients with known or suspected HIT. SUMMARY: A 33-year-old male was transferred to our institution and emergently initiated on life support with venoarterial extracorporeal membrane oxygenation (ECMO), an Impella pVAD, and continuous venovenous hemofiltration to receive an urgent aortic valve replacement. Over the next several days, the patient's platelet count declined with a nadir of 17 × 103/μL on hospital day 13. The patient's 4T score for probability of HIT was calculated as 4. All heparin products were discontinued on hospital day 15, and the patient was initiated on systemic infusion with argatroban 1,000 μg/mL at a rate of 0.2 μg/kg/min with a purge solution of argatroban 0.05 mg/mL. The systemic infusion remained at a rate of 0.2 μg/kg/min, and the total argatroban dose was, on average, less than 0.25 μg/kg/min. On hospital day 21, the patient was transferred to another institution. CONCLUSION: Systemic infusion and a purge solution with argatroban were used in a patient with an Impella pVAD with multisystem organ dysfunction and suspected HIT. The patient achieved therapeutic activated partial thromboplastin times without adjustment of the systemic argatroban infusion and did not experience bleeding or thrombosis. Further studies concerning the safety and effectiveness of argatroban-based purge solutions in patients with pVADs are needed.
引用
- Shtoyko AN, Feldman EA, Cwikla GM, et al. Use of an argatroban systemic infusion and purge solution in a patient with a percutaneous ventricular assist device with suspected heparin-induced thrombocytopenia. Am J Health Syst Pharm. 2022. PMID: 34390237. doi:10.1093/ajhp/zxab331
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。